Category Archives: Pharmaceuticals

Painted as the Latest Pharma Scoundrel, Mylan’s CEO Bresch Isn’t Buying It; She’s Got a Point, Maybe

Last week Mylan pharmaceuticals CEO Heather Bresch seemingly attained a status of villainy synonymous with Lance Armstrong and, more recently, Ryan Lochte, with news stories of its fourfold price increase… Read more »

Mylan to Reduce Cost of EpiPen as Pressure Mounts; Not All Patients to Benefit

Mylan NV (Amsterdam) on Thursday took some steps to alleviate patients’ cost burden for its $600 EpiPen emergency allergy shots following pressure from politicians including presidential candidate Hillary Clinton, who… Read more »

Drugmakers’ Pricing Power Helped by Exclusivity Rights: JAMA

The U.S., which spends more on drugs than any other country, might contain costs by limiting market exclusivity for brand-name medicines and changing coverage requirements for government health plans, some… Read more »

Pfizer Wins Bidding War for Medivation; But Why Bother?

Pharmaceutical giant Pfizer Inc. (New York City) is paying $14 billion to buy Medivation Inc. (San Francisco), a biotech company that sells a high-priced prostate cancer medication discovered by UCLA, according to the… Read more »

DEA Ignores the Evidence; Keeps Marijuana on Parity with Heroin

In a long-awaited announcement, the U.S. Drug Enforcement Administration denied requests to loosen the classification of marijuana as a dangerous drug with no medical use. The decision, reported by Reuters,… Read more »

Glaxo, Google Parent Create $715 Million Bioelectronic Medicines Venture

GlaxoSmithKline PLC (London) and Google parent Alphabet Inc. (Mountain View CA) have teamed up to develop what they call bioelectronic medicines, or treatments that use miniature implanted electronic devices to modify how electrical impulses are… Read more »

Valeant Plummets on Criminal Probe of Philidor Unit

Valeant Pharmaceuticals International Inc. (Laval Quebec) did an about-face and fell 11% on Thursday as new details about a criminal investigation into the drugmaker reignited investor concerns about the company’s… Read more »

Bristol-Myers’ Opdivo Fails in Key Lung-Cancer Study; Shares Plunge, as Do Patients’ Hopes

A cancer drug’s surprise failure in a clinical trial erased $20 billion from Bristol-Myers Squibb Co.’s (New York City) market value Friday, and raised serious questions about one of the industry’s… Read more »

FDA Panel Supports Novartis Version of Amgen Arthritis Drug

By unanimous FDA panel vote, Novartis AG’s (Basel CHE) Enbrel (etanercept) biosimilar was approved across all of its U.S. licenses. The panel, which gives nonbinding advice to the agency, voted… Read more »

GE Healthcare Barges into Cell-Therapy Arena with Swiss Buy; Where’s the FDA?

GE Healthcare (Little Chalfont GBR) just signaled its intention to build a $1 billion business which offers specialized manufacturing tools for an upcoming tidal wave of cell therapies by acquiring… Read more »